Hainan Honz Pharmaceutical Co Net Assets
Hainan Honz Pharmaceutical Co net assets. Based on the latest financial reports, Hainan Honz Pharmaceutical Co (300086) has net assets worth CN¥887.65 Million CNY (≈ $129.89 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.71 Billion ≈ $250.47 Million USD) and total liabilities (CN¥824.00 Million ≈ $120.58 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore 300086 year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥887.65 Million |
| % of Total Assets | 51.86% |
| Annual Growth Rate | 12.21% |
| 5-Year Change | -40.71% |
| 10-Year Change | -50.81% |
| Growth Volatility | 151.91 |
Net Assets of Hainan Honz Pharmaceutical Co (2007–2025)
Net assets of Hainan Honz Pharmaceutical Co from 2007 to 2025. This chart illustrates how Hainan Honz Pharmaceutical Co's net assets have evolved over time, based on quarterly financial data. See Hainan Honz Pharmaceutical Co balance sheet quality to measure how much of total assets are equity-financed.
Annual Net Assets for Hainan Honz Pharmaceutical Co (2007–2025)
The table below shows the annual net assets of Hainan Honz Pharmaceutical Co from 2007 to 2025. For live market cap and overall valuation, see 300086 market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥921.22 Million ≈ $134.80 Million |
-20.95% |
| 2024-12-31 | CN¥1.17 Billion ≈ $170.52 Million |
-15.44% |
| 2023-12-31 | CN¥1.38 Billion ≈ $201.65 Million |
+1.66% |
| 2022-12-31 | CN¥1.36 Billion ≈ $198.35 Million |
-12.75% |
| 2021-12-31 | CN¥1.55 Billion ≈ $227.35 Million |
-3.00% |
| 2020-12-31 | CN¥1.60 Billion ≈ $234.39 Million |
0.00% |
| 2019-12-31 | CN¥1.60 Billion ≈ $234.40 Million |
-3.13% |
| 2018-12-31 | CN¥1.65 Billion ≈ $241.97 Million |
-13.91% |
| 2017-12-31 | CN¥1.92 Billion ≈ $281.05 Million |
+2.57% |
| 2016-12-31 | CN¥1.87 Billion ≈ $274.03 Million |
+1.68% |
| 2015-12-31 | CN¥1.84 Billion ≈ $269.49 Million |
+2.05% |
| 2014-12-31 | CN¥1.80 Billion ≈ $264.07 Million |
-0.30% |
| 2013-12-31 | CN¥1.81 Billion ≈ $264.88 Million |
-3.39% |
| 2012-12-31 | CN¥1.87 Billion ≈ $274.16 Million |
+1.06% |
| 2011-12-31 | CN¥1.85 Billion ≈ $271.29 Million |
+1.39% |
| 2010-12-31 | CN¥1.83 Billion ≈ $267.58 Million |
+660.36% |
| 2009-12-31 | CN¥240.49 Million ≈ $35.19 Million |
+59.89% |
| 2008-12-31 | CN¥150.41 Million ≈ $22.01 Million |
+29.79% |
| 2007-12-31 | CN¥115.89 Million ≈ $16.96 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Hainan Honz Pharmaceutical Co's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 183287.2% over the analyzed period, potentially due to dividend distributions or operating losses.
Hainan Honz Pharmaceutical Co Net Assets Breakdown (December 2025)
Hainan Honz Pharmaceutical Co net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | CN¥1.42 Billion | 157.73% |
| Total Equity | CN¥899.71 Million | 100.00% |
Hainan Honz Pharmaceutical Co Competitors by Market Cap
The table below lists competitors of Hainan Honz Pharmaceutical Co ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
JTL Industries Ltd
NSE:JTLIND
|
$314.36 Million |
|
Hanyang ENG Co. Ltd
KQ:045100
|
$314.68 Million |
|
International CSRC Investment Holdings Co Ltd
TW:2104
|
$314.77 Million |
|
ABC arbitrage SA
PA:ABCA
|
$314.86 Million |
|
Tanzanian Royalty Exploration Corp
NYSE MKT:TRX
|
$314.28 Million |
|
Shenzhen Longood Intelligent Electric Co Ltd Class A
SHE:300543
|
$314.27 Million |
|
Itcen Co. Ltd
KQ:124500
|
$314.19 Million |
|
Lontrue Co Ltd
SHE:300175
|
$314.15 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Hainan Honz Pharmaceutical Co's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,139,922,413 to 899,709,487, a change of -240,212,926 (-21.1%).
- Net loss of 230,138,659 reduced equity.
- Dividend payments of 16,490,585 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-230.14 Million | -25.58% |
| Dividends Paid | CN¥16.49 Million | -1.83% |
| Other Changes | CN¥6.42 Million | +0.71% |
| Total Change | CN¥- | -21.07% |
Book Value vs Market Value Analysis
This analysis compares Hainan Honz Pharmaceutical Co's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.39x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 12.29x to 2.39x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-12-31 | CN¥0.38 | CN¥4.72 | x |
| 2008-12-31 | CN¥0.45 | CN¥4.72 | x |
| 2009-12-31 | CN¥0.71 | CN¥4.72 | x |
| 2010-12-31 | CN¥4.54 | CN¥4.72 | x |
| 2011-12-31 | CN¥3.94 | CN¥4.72 | x |
| 2012-12-31 | CN¥3.98 | CN¥4.72 | x |
| 2013-12-31 | CN¥3.84 | CN¥4.72 | x |
| 2014-12-31 | CN¥3.83 | CN¥4.72 | x |
| 2015-12-31 | CN¥3.91 | CN¥4.72 | x |
| 2016-12-31 | CN¥4.00 | CN¥4.72 | x |
| 2017-12-31 | CN¥4.11 | CN¥4.72 | x |
| 2018-12-31 | CN¥3.43 | CN¥4.72 | x |
| 2019-12-31 | CN¥3.33 | CN¥4.72 | x |
| 2020-12-31 | CN¥3.35 | CN¥4.72 | x |
| 2021-12-31 | CN¥3.34 | CN¥4.72 | x |
| 2022-12-31 | CN¥2.93 | CN¥4.72 | x |
| 2023-12-31 | CN¥2.99 | CN¥4.72 | x |
| 2024-12-31 | CN¥2.50 | CN¥4.72 | x |
| 2025-12-31 | CN¥1.98 | CN¥4.72 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Hainan Honz Pharmaceutical Co utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -25.58%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -49.37%
- • Asset Turnover: 0.26x
- • Equity Multiplier: 1.99x
- Recent ROE (-25.58%) is below the historical average (3.59%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | 29.51% | 35.64% | 0.68x | 1.22x | CN¥22.61 Million |
| 2008 | 32.93% | 36.46% | 0.66x | 1.37x | CN¥34.48 Million |
| 2009 | 40.57% | 44.60% | 0.74x | 1.22x | CN¥73.53 Million |
| 2010 | 7.62% | 44.30% | 0.17x | 1.04x | CN¥-43.54 Million |
| 2011 | -0.06% | -0.37% | 0.15x | 1.11x | CN¥-177.88 Million |
| 2012 | 1.26% | 6.12% | 0.19x | 1.10x | CN¥-156.42 Million |
| 2013 | 0.86% | 4.80% | 0.16x | 1.10x | CN¥-157.85 Million |
| 2014 | 3.60% | 15.20% | 0.21x | 1.12x | CN¥-110.29 Million |
| 2015 | 3.87% | 16.64% | 0.20x | 1.19x | CN¥-108.01 Million |
| 2016 | 2.56% | 9.79% | 0.22x | 1.22x | CN¥-133.91 Million |
| 2017 | 3.00% | 8.31% | 0.30x | 1.21x | CN¥-129.54 Million |
| 2018 | 0.87% | 1.51% | 0.40x | 1.41x | CN¥-141.05 Million |
| 2019 | -1.77% | -2.62% | 0.46x | 1.46x | CN¥-176.31 Million |
| 2020 | 0.62% | 1.01% | 0.35x | 1.74x | CN¥-140.91 Million |
| 2021 | 0.73% | 1.31% | 0.34x | 1.63x | CN¥-139.41 Million |
| 2022 | -14.25% | -35.01% | 0.23x | 1.74x | CN¥-319.20 Million |
| 2023 | 0.86% | 1.56% | 0.34x | 1.61x | CN¥-122.95 Million |
| 2024 | -18.97% | -45.73% | 0.24x | 1.73x | CN¥-330.20 Million |
| 2025 | -25.58% | -49.37% | 0.26x | 1.99x | CN¥-320.11 Million |
Industry Comparison
This section compares Hainan Honz Pharmaceutical Co's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $3,632,405,673
- Average return on equity (ROE) among peers: 7.53%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Hainan Honz Pharmaceutical Co (300086) | CN¥887.65 Million | 29.51% | 0.93x | $314.35 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $1.97 Billion | 4.04% | 0.54x | $488.97 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $560.87 Million | 4.60% | 0.22x | $360.39 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $1.02 Billion | 12.46% | 0.13x | $4.73 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $1.04 Billion | 4.29% | 0.46x | $2.58 Billion |
| Wedge Industrial Co Ltd (000534) | $0.00 | 0.00% | 0.00x | $1.20 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $18.14 Billion | 17.33% | 0.53x | $14.52 Billion |
| Hainan Haiyao Co Ltd (000566) | $491.82 Million | 6.71% | 1.19x | $755.58 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $280.91 Million | 1.46% | 1.58x | $272.98 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $5.57 Billion | 7.36% | 1.59x | $920.83 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $7.25 Billion | 17.08% | 0.09x | $3.02 Billion |
About Hainan Honz Pharmaceutical Co
Honz Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pediatric medicines in China and internationally. It operates through Pharmaceutical Manufacturing and Sales; and Daily Necessities Manufacturing and Sales segments. The company offers medicines for children and adults in the areas of anti-anaphylaxis, antidiarrheal, cough … Read more